Adaptive Biotech Stock Reaches $26.89 52-Week High

Adaptive Biotechnologies Corporation (ADPT) saw its stock climb to a 52-week high of $26.89 on September 15, 2026, closing at $26.90. The biotech firm’s shares have surged significantly over the past year, reflecting robust financial performance and investor confidence. Over the last 12 months, the company’s total return reached 89.45%, with six-month returns at 88.15%. Revenue growth over the same period was 50.13%, driven by its core minimal residual disease (MRD) business, which grew 49% year-over-year, and its clonoSEQ MRD test franchise, which expanded by 43%. In Q2 2026, revenue increased 22% year-over-year to $71.6 million, exceeding analyst estimates of $65.8 million and up from $58.7 million in the prior-year quarter. Despite an adjusted loss of $0.25 per share—above the $0.14 per share loss estimate—analysts remain optimistic. BTIG raised its price target to $25 from $24 and maintained a Buy rating, while Guggenheim increased its target to $25 from $22, also keeping a Buy stance. Seven analysts revised their earnings expectations upward for the upcoming period, further signaling positive momentum. The stock’s beta of 2.1 underscores higher volatility compared to the broader market, reflecting its growth-driven trajectory.